Mina Mar Marketing – Blog & Announcements

FUZHOU CITY, China, Dec 23, 2009 /PRNewswire-FirstCall via COMTEX/ — Hiru Corporation (HIRU; www.hirucorporation.com) intends to acquire an east European emerging market Medical Bioresearch company on cash and stock basis (80% cash and 20% stock).

This company focuses on research of new therapeutics that would overcome the Cancer Cell Resistance in chemotherapy and also conducts research on identification of genes connected with lung cancer.

Mr. Ye Rongyu, The CEO of Hiru Corporation, said, “We are quite flattered that our all cash offer was signed back where the seller is asking for some stock of HIRU. Originally the seller was asking for 100% payment in HIRU stock as consideration. I guess this only validates our opinion that HIRU is grossly undervalued and many see great upward momentum with HIRU. By acquiring this entity, we expand our playing field and participate in the international medical markets. This is a promising start for HIRU, and we intend to pursue our goal to penetrate the international medical community. The research company has great potential and we will be there when their research and development of customized cancer treatment bears fruit. We see it as an “elevator up, or hyper growth” acquisition, where our Jianxi RongYu Pharmaceutical Group, Inc. will provide the staple – the stable revenues and growth to HIRU.”

The Hiru Corporation management feels that this is a material event and that this stage with the new company requires a public announcement.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates